Press Release|Articles|October 30, 2025
Camber Launches Abacavir and Lamivudine Tablets, USP
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP, for treating HIV-1 infection, enhancing access to essential treatments.
- The tablets contain 600 mg Abacavir and 300 mg Lamivudine, supplied in bottles of 30 tablets.
Advertisement
Continuing its mission to expand access to essential treatments, Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP [a-BAK-a-veer-and-la-MIV-yoo-deen] to its portfolio.
Abacavir/Lamivudine Tablets, USP are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Camber's Abacavir and Lamivudine Tablets, USP (600 mg/300 mg) are supplied in bottles of 30 tablets.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
FDA Approves First At-Home Treatment Device for Depression
5
